280 related articles for article (PubMed ID: 23324344)
21. Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers.
Kim KH; Jo MS; Suh DS; Yoon MS; Shin DH; Lee JH; Choi KU
World J Surg Oncol; 2012 Sep; 10():193. PubMed ID: 22985132
[TBL] [Abstract][Full Text] [Related]
22. Spheroid body-forming cells in the human gastric cancer cell line MKN-45 possess cancer stem cell properties.
Liu J; Ma L; Xu J; Liu C; Zhang J; Liu J; Chen R; Zhou Y
Int J Oncol; 2013 Feb; 42(2):453-9. PubMed ID: 23229446
[TBL] [Abstract][Full Text] [Related]
23. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals.
Chen SS; Michael A; Butler-Manuel SA
Discov Med; 2012 Jan; 13(68):7-17. PubMed ID: 22284780
[TBL] [Abstract][Full Text] [Related]
24. 1α,25‑Dihydroxyvitamin D3 restrains stem cell‑like properties of ovarian cancer cells by enhancing vitamin D receptor and suppressing CD44.
Ji M; Liu L; Hou Y; Li B
Oncol Rep; 2019 Jun; 41(6):3393-3403. PubMed ID: 31002352
[TBL] [Abstract][Full Text] [Related]
25. Snail Driving Alternative Splicing of CD44 by ESRP1 Enhances Invasion and Migration in Epithelial Ovarian Cancer.
Chen L; Yao Y; Sun L; Zhou J; Miao M; Luo S; Deng G; Li J; Wang J; Tang J
Cell Physiol Biochem; 2017; 43(6):2489-2504. PubMed ID: 29131012
[TBL] [Abstract][Full Text] [Related]
26. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
Choi EJ; Seo EJ; Kim DK; Lee SI; Kwon YW; Jang IH; Kim KH; Suh DS; Kim JH
Oncotarget; 2016 Jan; 7(3):3506-19. PubMed ID: 26654944
[TBL] [Abstract][Full Text] [Related]
27. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.
Chen X; Zhang J; Zhang Z; Li H; Cheng W; Liu J
Hum Pathol; 2013 Nov; 44(11):2373-84. PubMed ID: 23850493
[TBL] [Abstract][Full Text] [Related]
28. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo.
Alvero AB; Heaton A; Lima E; Pitruzzello M; Sumi N; Yang-Hartwich Y; Cardenas C; Steinmacher S; Silasi DA; Brown D; Mor G
Mol Cancer Ther; 2016 Jun; 15(6):1279-90. PubMed ID: 27196760
[TBL] [Abstract][Full Text] [Related]
29. HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way.
Wang W; Gao Y; Hai J; Yang J; Duan S
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30314995
[TBL] [Abstract][Full Text] [Related]
30. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells.
Zhu Y; Huang JM; Zhang GN; Zha X; Deng BF
J Transl Med; 2012 Apr; 10():77. PubMed ID: 22533866
[TBL] [Abstract][Full Text] [Related]
32. Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate.
Wintzell M; Löfstedt L; Johansson J; Pedersen AB; Fuxe J; Shoshan M
Cancer Biol Ther; 2012 Dec; 13(14):1454-62. PubMed ID: 22954696
[TBL] [Abstract][Full Text] [Related]
33. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinase-10 regulates stemness of ovarian cancer stem-like cells by activation of canonical Wnt signaling and can be a target of chemotherapy-resistant ovarian cancer.
Mariya T; Hirohashi Y; Torigoe T; Tabuchi Y; Asano T; Saijo H; Kuroda T; Yasuda K; Mizuuchi M; Saito T; Sato N
Oncotarget; 2016 May; 7(18):26806-22. PubMed ID: 27072580
[TBL] [Abstract][Full Text] [Related]
35. Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer.
Belotte J; Fletcher NM; Alexis M; Morris RT; Munkarah AR; Diamond MP; Saed GM
Reprod Sci; 2015 Jan; 22(1):38-46. PubMed ID: 25038052
[TBL] [Abstract][Full Text] [Related]
36. Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer.
Zhang QH; Dou HT; Xu P; Zhuang SC; Liu PS
Drug Res (Stuttg); 2015 Mar; 65(3):153-7. PubMed ID: 25504004
[TBL] [Abstract][Full Text] [Related]
37. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
Alberti L; Losi L; Leyvraz S; Benhattar J
PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
[TBL] [Abstract][Full Text] [Related]
38. Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm.
Garson K; Vanderhyden BC
Reproduction; 2015 Feb; 149(2):R59-70. PubMed ID: 25301968
[TBL] [Abstract][Full Text] [Related]
39. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N; Abubaker K; Findlay J; Quinn M
J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
[TBL] [Abstract][Full Text] [Related]
40. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
